0000766704false2024Q1December 31P1Yhttp://www.welltower.com/20240331#LeaseRightOfUseAssethttp://www.welltower.com/20240331#LeaseRightOfUseAssethttp://www.welltower.com/20240331#LeaseRightOfUseAssethttp://www.welltower.com/20240331#LeaseRightOfUseAssethttp://www.welltower.com/20240331#ReceivablesAndOtherAssetshttp://www.welltower.com/20240331#ReceivablesAndOtherAssetshttp://www.welltower.com/20240331#LeaseLiabilityhttp://www.welltower.com/20240331#LeaseLiabilityhttp://www.welltower.com/20240331#LeaseLiabilityhttp://www.welltower.com/20240331#LeaseLiabilityP3Y00007667042024-01-012024-03-310000766704us-gaap:CommonStockMember2024-01-012024-03-310000766704well:GuaranteeNotesDue20284800Member2024-01-012024-03-310000766704well:GuaranteeNotesDue20344500Member2024-01-012024-03-3100007667042024-04-26xbrli:shares00007667042024-03-31iso4217:USD00007667042023-12-3100007667042023-01-012023-03-31iso4217:USDxbrli:shares0000766704us-gaap:CommonStockMember2023-12-310000766704us-gaap:AdditionalPaidInCapitalMember2023-12-310000766704us-gaap:TreasuryStockCommonMember2023-12-310000766704us-gaap:RetainedEarningsUnappropriatedMember2023-12-310000766704well:AccumulatedDistributionsMember2023-12-310000766704us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000766704us-gaap:NoncontrollingInterestMember2023-12-310000766704us-gaap:RetainedEarningsUnappropriatedMember2024-01-012024-03-310000766704us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000766704us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000766704us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000766704us-gaap:CommonStockMember2024-01-012024-03-310000766704us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000766704well:AccumulatedDistributionsMember2024-01-012024-03-310000766704us-gaap:CommonStockMember2024-03-310000766704us-gaap:AdditionalPaidInCapitalMember2024-03-310000766704us-gaap:TreasuryStockCommonMember2024-03-310000766704us-gaap:RetainedEarningsUnappropriatedMember2024-03-310000766704well:AccumulatedDistributionsMember2024-03-310000766704us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000766704us-gaap:NoncontrollingInterestMember2024-03-310000766704us-gaap:CommonStockMember2022-12-310000766704us-gaap:AdditionalPaidInCapitalMember2022-12-310000766704us-gaap:TreasuryStockCommonMember2022-12-310000766704us-gaap:RetainedEarningsUnappropriatedMember2022-12-310000766704well:AccumulatedDistributionsMember2022-12-310000766704us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000766704us-gaap:NoncontrollingInterestMember2022-12-3100007667042022-12-310000766704us-gaap:RetainedEarningsUnappropriatedMember2023-01-012023-03-310000766704us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000766704us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000766704us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000766704us-gaap:CommonStockMember2023-01-012023-03-310000766704us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000766704well:AccumulatedDistributionsMember2023-01-012023-03-310000766704us-gaap:CommonStockMember2023-03-310000766704us-gaap:AdditionalPaidInCapitalMember2023-03-310000766704us-gaap:TreasuryStockCommonMember2023-03-310000766704us-gaap:RetainedEarningsUnappropriatedMember2023-03-310000766704well:AccumulatedDistributionsMember2023-03-310000766704us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000766704us-gaap:NoncontrollingInterestMember2023-03-3100007667042023-03-310000766704well:WelltowerOPIncMember2024-01-012024-03-31xbrli:pure0000766704well:WelltowerOPIncMember2024-03-310000766704well:OtherInvestorsMemberwell:WelltowerOPIncMember2024-03-310000766704well:SeniorHousingOperatingMember2024-03-310000766704well:TripleNetMember2024-03-310000766704well:OutpatientMedicalMember2024-03-310000766704well:SeniorHousingOperatingMember2023-03-310000766704well:TripleNetMember2023-03-310000766704well:OutpatientMedicalMember2023-03-310000766704well:SeniorHousingOperatingMember2024-01-012024-03-310000766704well:TripleNetMember2024-01-012024-03-310000766704well:OutpatientMedicalMember2024-01-012024-03-310000766704well:SeniorHousingOperatingMember2023-01-012023-03-310000766704well:TripleNetMember2023-01-012023-03-310000766704well:OutpatientMedicalMember2023-01-012023-03-310000766704well:SeniorsHousingOperatingPropertiesAffinityBrandMember2024-02-29well:property0000766704well:SeniorsHousingOperatingPropertiesAffinityBrandMember2024-02-012024-02-290000766704us-gaap:LeasesAcquiredInPlaceMember2024-03-310000766704us-gaap:LeasesAcquiredInPlaceMember2023-12-310000766704us-gaap:AboveMarketLeasesMember2024-03-310000766704us-gaap:AboveMarketLeasesMember2023-12-310000766704well:LeaseCommissionsMember2024-03-310000766704well:LeaseCommissionsMember2023-12-310000766704us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-03-310000766704well:ReveraJointVentureDisposalTransactionMember2023-01-012023-12-310000766704us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2024-01-012024-03-310000766704us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2023-01-012023-03-310000766704well:ReveraJointVentureAcquisitionTransactionMember2023-04-012023-06-300000766704well:ReveraJointVentureDisposalTransactionMember2023-04-012023-06-300000766704well:ReveraJointVentureAcquisitionTransactionMember2023-06-012023-06-300000766704well:UKPortfolioReveraJointVentureMember2023-06-30well:joint_venture0000766704well:UKPortfolioReveraJointVenture1Member2023-06-300000766704well:UKPortfolioReveraJointVenture2Member2023-06-300000766704well:ReveraJointVentureDisposalTransactionMember2023-06-012023-06-300000766704well:UKPortfolioReveraJointVenture1Member2023-06-012023-06-300000766704well:AveryHealthcareMemberwell:ReveraJointVentureDisposalTransactionMember2023-06-012023-06-300000766704well:ReveraJointVentureDisposalTransactionMember2023-06-300000766704well:ReveraJointVentureAcquisitionTransactionMember2023-07-012023-09-300000766704well:USPortfolioReveraJointVentureMember2023-09-300000766704well:ReveraMemberwell:USPortfolioReveraJointVentureMember2023-09-300000766704well:ReveraJointVentureDisposalTransactionUSPropertiesMember2023-07-012023-09-300000766704well:ReveraJointVentureDisposalTransactionMember2023-07-012023-09-30well:project0000766704well:ReveraJointVentureAcquisitionTransactionMember2023-09-300000766704well:ReveraJointVentureDisposalTransactionMember2023-09-300000766704well:OakmontManagementGroupMemberwell:ReveraJointVentureDisposalTransactionNowWhollyOwnedPropertiesMember2023-07-012023-09-300000766704well:OakmontManagementGroupMemberwell:ReveraJointVentureDisposalTransactionExistingWhollyOwnedPropertiesMember2023-07-012023-09-300000766704well:CanadianPortfolioReveraJointVentureMember2023-09-300000766704well:CanadianPortfolioReveraJointVentureMemberwell:ReveraMember2023-09-300000766704well:ReveraJointVentureAcquisitionTransactionMemberus-gaap:SubsequentEventMember2024-04-012024-04-010000766704well:ReveraJointVentureDisposalTransactionMemberus-gaap:SubsequentEventMember2024-04-012024-04-010000766704srt:MinimumMember2024-01-012024-03-310000766704srt:MaximumMember2024-01-012024-03-310000766704us-gaap:CostOfSalesMember2024-01-012024-03-310000766704us-gaap:CostOfSalesMember2023-01-012023-03-310000766704us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310000766704us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310000766704us-gaap:OperatingSegmentsMember2024-03-310000766704us-gaap:OperatingSegmentsMember2023-12-310000766704us-gaap:CorporateNonSegmentMember2024-03-310000766704us-gaap:CorporateNonSegmentMember2023-12-310000766704well:OperatingSegmentsAndCorporateNonSegmentMember2024-03-310000766704well:OperatingSegmentsAndCorporateNonSegmentMember2023-12-310000766704us-gaap:MortgageReceivablesMember2024-03-310000766704us-gaap:MortgageReceivablesMember2023-12-310000766704well:OtherRealEstateLoansReceivablesMember2024-03-310000766704well:OtherRealEstateLoansReceivablesMember2023-12-310000766704us-gaap:RealEstateLoanMember2024-03-310000766704us-gaap:RealEstateLoanMember2023-12-310000766704well:DeterioratedLoansMember2024-03-31well:loan0000766704well:CollectiveLoanPool1Member2024-03-310000766704well:CollectiveLoanPool2Member2024-03-310000766704well:CollectiveLoanPool3Member2024-03-310000766704well:CollectiveLoanPool4Member2024-03-310000766704well:CollectiveLoanPool5Member2024-03-310000766704well:CollectiveLoanPool6Member2024-03-310000766704us-gaap:RealEstateLoanMember2024-03-310000766704well:SecuredAndUnsecuredDebtMemberwell:GenesisHealthCareCorporationMember2024-03-310000766704srt:MinimumMemberwell:SeniorsHousingOperatingMember2024-03-310000766704well:SeniorsHousingOperatingMembersrt:MaximumMember2024-03-310000766704well:SeniorsHousingOperatingMember2024-03-310000766704well:SeniorsHousingOperatingMember2023-12-310000766704well:TripleNetMembersrt:MinimumMember2024-03-310000766704well:TripleNetMembersrt:MaximumMember2024-03-310000766704well:TripleNetMember2024-03-310000766704well:TripleNetMember2023-12-310000766704srt:MinimumMemberwell:OutpatientMedicalMember2024-03-310000766704well:OutpatientMedicalMembersrt:MaximumMember2024-03-310000766704well:OutpatientMedicalMember2024-03-310000766704well:OutpatientMedicalMember2023-12-310000766704us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-03-31well:properties0000766704us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-01-012024-03-310000766704well:NetOperatingingIncomeMemberwell:CogirManagementCorporationMemberus-gaap:CreditConcentrationRiskMember2024-03-310000766704well:NetOperatingingIncomeMemberwell:CogirManagementCorporationMemberus-gaap:CreditConcentrationRiskMember2024-01-012024-03-310000766704well:NetOperatingingIncomeMemberwell:IntegraHealthcarePropertiesMemberus-gaap:CreditConcentrationRiskMember2024-03-310000766704well:NetOperatingingIncomeMemberwell:IntegraHealthcarePropertiesMemberus-gaap:CreditConcentrationRiskMember2024-01-012024-03-310000766704well:SunriseSeniorLivingMemberwell:NetOperatingingIncomeMemberus-gaap:CreditConcentrationRiskMember2024-03-310000766704well:SunriseSeniorLivingMemberwell:NetOperatingingIncomeMemberus-gaap:CreditConcentrationRiskMember2024-01-012024-03-310000766704well:NetOperatingingIncomeMemberwell:AveryHealthcare1Memberus-gaap:CreditConcentrationRiskMember2024-03-310000766704well:NetOperatingingIncomeMemberwell:AveryHealthcare1Memberus-gaap:CreditConcentrationRiskMember2024-01-012024-03-310000766704well:OakmontManagementGroupMemberwell:NetOperatingingIncomeMemberus-gaap:CreditConcentrationRiskMember2024-03-310000766704well:OakmontManagementGroupMemberwell:NetOperatingingIncomeMemberus-gaap:CreditConcentrationRiskMember2024-01-012024-03-310000766704well:NetOperatingingIncomeMemberus-gaap:CreditConcentrationRiskMemberwell:RemainingPortfolioMember2024-03-310000766704well:NetOperatingingIncomeMemberus-gaap:CreditConcentrationRiskMemberwell:RemainingPortfolioMember2024-01-012024-03-310000766704well:NetOperatingingIncomeMemberus-gaap:CreditConcentrationRiskMember2024-03-310000766704well:NetOperatingingIncomeMemberus-gaap:CreditConcentrationRiskMember2024-01-012024-03-31well:bank0000766704us-gaap:RevolvingCreditFacilityMember2024-03-310000766704well:TermCreditFacilityMember2024-03-310000766704well:TermCreditFacilityCADDenominatedMember2024-03-31iso4217:CAD0000766704us-gaap:RevolvingCreditFacilityMemberwell:CreditFacilityTrancheDue2026Member2024-03-310000766704us-gaap:RevolvingCreditFacilityMemberwell:CreditFacilityTrancheDue2025Member2024-03-31well:Term0000766704us-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310000766704us-gaap:RevolvingCreditFacilityMemberwell:AccordionfeaturememberMember2024-03-310000766704well:TermCreditFacilityCADDenominatedMemberwell:AccordionfeaturememberMember2024-03-310000766704us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2024-01-012024-03-310000766704srt:MaximumMemberus-gaap:CommercialPaperMember2024-01-012024-03-310000766704us-gaap:CommercialPaperMember2024-03-310000766704us-gaap:UnsecuredDebtMember2024-03-310000766704us-gaap:SecuredDebtMember2024-03-310000766704srt:MinimumMemberus-gaap:UnsecuredDebtMember2024-03-310000766704srt:MaximumMemberus-gaap:UnsecuredDebtMember2024-03-310000766704us-gaap:UnsecuredDebtMember2023-03-310000766704well:A295SeniorUnsecuredNotesDue2023Memberus-gaap:UnsecuredDebtMember2024-03-310000766704srt:MinimumMemberus-gaap:SecuredDebtMember2024-03-310000766704us-gaap:SecuredDebtMembersrt:MaximumMember2024-03-310000766704us-gaap:SecuredDebtMember2023-03-310000766704us-gaap:UnsecuredDebtMemberwell:UnsecuredTermCreditFacilityMaturesJuly192023Member2024-03-310000766704well:TermLoanMemberus-gaap:UnsecuredDebtMember2024-03-31well:term0000766704well:TermLoanMemberus-gaap:UnsecuredDebtMember2024-01-012024-03-310000766704well:TermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:UnsecuredDebtMember2024-01-012024-03-310000766704us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberwell:UnsecuredTermCreditFacilityMaturesJuly192023Memberus-gaap:UnsecuredDebtMember2024-03-310000766704well:CanadianDealerOfferedRateMemberwell:TermLoanMemberus-gaap:UnsecuredDebtMember2024-01-012024-03-310000766704well:CanadianDealerOfferedRateMemberwell:TermLoanMemberus-gaap:UnsecuredDebtMember2024-03-310000766704well:UkDebtDue2028Memberus-gaap:UnsecuredDebtMember2024-03-31iso4217:GBP0000766704well:A450SeniorUnsecuredNotesDue2034Memberus-gaap:UnsecuredDebtMember2024-03-310000766704us-gaap:UnsecuredDebtMember2023-12-310000766704us-gaap:UnsecuredDebtMember2022-12-310000766704us-gaap:UnsecuredDebtMember2024-01-012024-03-310000766704us-gaap:UnsecuredDebtMember2023-01-012023-03-310000766704well:A2750SeniorUnsecuredNotesDue2028Memberus-gaap:UnsecuredDebtMember2023-05-310000766704well:A2750SeniorUnsecuredNotesDue2028Memberus-gaap:UnsecuredDebtMember2024-01-012024-03-310000766704well:A2750SeniorUnsecuredNotesDue2028Memberus-gaap:UnsecuredDebtMember2024-03-310000766704well:A2750SeniorUnsecuredNotesDue2028Memberus-gaap:UnsecuredDebtMember2023-12-310000766704us-gaap:SecuredDebtMember2023-12-310000766704us-gaap:SecuredDebtMember2022-12-310000766704us-gaap:SecuredDebtMember2024-01-012024-03-310000766704us-gaap:SecuredDebtMember2023-01-012023-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2024-01-012024-01-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2024-01-012024-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2024-01-310000766704well:A2.8SeniorUnsecuredNotesMemberus-gaap:UnsecuredDebtMember2024-03-310000766704us-gaap:InterestRateSwapMember2024-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercurrency:CAD2024-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercurrency:CAD2023-12-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercurrency:GBP2024-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercurrency:GBP2023-12-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercurrency:CAD2024-01-012024-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercurrency:CAD2023-01-012023-12-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercurrency:GBP2024-01-012024-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMembercurrency:GBP2023-01-012023-12-310000766704us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:USD2024-03-310000766704us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:USD2023-12-310000766704us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:USD2024-03-310000766704us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:USD2023-12-310000766704us-gaap:NondesignatedMembercurrency:CAD2024-03-310000766704us-gaap:NondesignatedMembercurrency:CAD2023-12-310000766704us-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-03-310000766704us-gaap:NondesignatedMember2024-01-012024-03-310000766704us-gaap:NondesignatedMember2023-01-012023-03-310000766704us-gaap:WarrantMember2024-01-012024-03-310000766704us-gaap:WarrantMember2023-01-012023-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember2024-01-012024-03-310000766704us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherComprehensiveIncomeMember2023-01-012023-03-31well:obligation0000766704well:SeniorsHousingOperatingPropertiesAffinityBrandMember2024-03-310000766704well:AtTheMarketProgramMember2024-02-290000766704well:AtTheMarketProgramMember2023-08-010000766704well:AtTheMarketProgramMember2024-03-310000766704us-gaap:SubsequentEventMemberwell:AtTheMarketProgramMember2024-04-012024-04-300000766704well:AtTheMarketProgramMember2023-01-012023-03-310000766704well:AtTheMarketProgramMember2023-03-310000766704well:AtTheMarketProgramMember2024-01-012024-03-310000766704us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000766704us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000766704us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000766704us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-3100007667042022-03-310000766704us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:MortgagesMember2024-03-310000766704us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MortgagesMember2024-03-310000766704us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:MortgagesMember2023-12-310000766704us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MortgagesMember2023-12-310000766704us-gaap:CarryingReportedAmountFairValueDisclosureMemberwell:OtherRealEstateLoansReceivableMember2024-03-310000766704us-gaap:EstimateOfFairValueFairValueDisclosureMemberwell:OtherRealEstateLoansReceivableMember2024-03-310000766704us-gaap:CarryingReportedAmountFairValueDisclosureMemberwell:OtherRealEstateLoansReceivableMember2023-12-310000766704us-gaap:EstimateOfFairValueFairValueDisclosureMemberwell:OtherRealEstateLoansReceivableMember2023-12-310000766704us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310000766704us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310000766704us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000766704us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000766704well:NonRealEstateLoansReceivablesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310000766704us-gaap:EstimateOfFairValueFairValueDisclosureMemberwell:NonRealEstateLoansReceivablesMember2024-03-310000766704well:NonRealEstateLoansReceivablesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000766704us-gaap:EstimateOfFairValueFairValueDisclosureMemberwell:NonRealEstateLoansReceivablesMember2023-12-310000766704us-gaap:FairValueInputsLevel1Member2024-03-310000766704us-gaap:FairValueInputsLevel2Member2024-03-310000766704us-gaap:FairValueInputsLevel3Member2024-03-310000766704us-gaap:WarrantMember2023-12-310000766704us-gaap:WarrantMember2022-12-310000766704us-gaap:WarrantMember2024-01-012024-03-310000766704us-gaap:WarrantMember2023-01-012023-03-310000766704us-gaap:WarrantMember2024-03-310000766704us-gaap:WarrantMember2023-03-310000766704well:TerminalCapitalizationRateMember2024-03-310000766704well:TerminalCapitalizationRateMember2023-03-31well:segment0000766704well:SeniorHousingOperatingMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310000766704us-gaap:OperatingSegmentsMemberwell:TripleNetMember2024-01-012024-03-310000766704us-gaap:OperatingSegmentsMemberwell:OutpatientMedicalMember2024-01-012024-03-310000766704us-gaap:CorporateNonSegmentMember2024-01-012024-03-310000766704well:SeniorHousingOperatingMemberus-gaap:OperatingSegmentsMember2024-03-310000766704us-gaap:OperatingSegmentsMemberwell:TripleNetMember2024-03-310000766704us-gaap:OperatingSegmentsMemberwell:OutpatientMedicalMember2024-03-310000766704well:SeniorHousingOperatingMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000766704us-gaap:OperatingSegmentsMemberwell:TripleNetMember2023-01-012023-03-310000766704us-gaap:OperatingSegmentsMemberwell:OutpatientMedicalMember2023-01-012023-03-310000766704us-gaap:CorporateNonSegmentMember2023-01-012023-03-310000766704country:US2024-01-012024-03-310000766704us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2024-01-012024-03-310000766704country:US2023-01-012023-03-310000766704us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2023-01-012023-03-310000766704country:GB2024-01-012024-03-310000766704us-gaap:GeographicConcentrationRiskMembercountry:GBus-gaap:SalesRevenueNetMember2024-01-012024-03-310000766704country:GB2023-01-012023-03-310000766704us-gaap:GeographicConcentrationRiskMembercountry:GBus-gaap:SalesRevenueNetMember2023-01-012023-03-310000766704country:CA2024-01-012024-03-310000766704country:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000766704country:CA2023-01-012023-03-310000766704country:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000766704us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000766704us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000766704us-gaap:ManagementServiceMembercountry:US2024-01-012024-03-310000766704us-gaap:ManagementServiceMemberus-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2024-01-012024-03-310000766704us-gaap:ManagementServiceMembercountry:US2023-01-012023-03-310000766704us-gaap:ManagementServiceMemberus-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2023-01-012023-03-310000766704us-gaap:ManagementServiceMembercountry:GB2024-01-012024-03-310000766704us-gaap:ManagementServiceMemberus-gaap:GeographicConcentrationRiskMembercountry:GBus-gaap:SalesRevenueNetMember2024-01-012024-03-310000766704us-gaap:ManagementServiceMembercountry:GB2023-01-012023-03-310000766704us-gaap:ManagementServiceMemberus-gaap:GeographicConcentrationRiskMembercountry:GBus-gaap:SalesRevenueNetMember2023-01-012023-03-310000766704country:CAus-gaap:ManagementServiceMember2024-01-012024-03-310000766704country:CAus-gaap:ManagementServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000766704country:CAus-gaap:ManagementServiceMember2023-01-012023-03-310000766704country:CAus-gaap:ManagementServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000766704us-gaap:ManagementServiceMember2024-01-012024-03-310000766704us-gaap:ManagementServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000766704us-gaap:ManagementServiceMember2023-01-012023-03-310000766704us-gaap:ManagementServiceMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000766704country:US2024-03-310000766704us-gaap:GeographicConcentrationRiskMemberus-gaap:AssetsTotalMembercountry:US2024-01-012024-03-310000766704country:US2023-12-310000766704us-gaap:GeographicConcentrationRiskMemberus-gaap:AssetsTotalMembercountry:US2023-01-012023-12-310000766704country:GB2024-03-310000766704us-gaap:GeographicConcentrationRiskMemberus-gaap:AssetsTotalMembercountry:GB2024-01-012024-03-310000766704country:GB2023-12-310000766704us-gaap:GeographicConcentrationRiskMemberus-gaap:AssetsTotalMembercountry:GB2023-01-012023-12-310000766704country:CA2024-03-310000766704country:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:AssetsTotalMember2024-01-012024-03-310000766704country:CA2023-12-310000766704country:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:AssetsTotalMember2023-01-012023-12-310000766704us-gaap:GeographicConcentrationRiskMemberus-gaap:AssetsTotalMember2024-01-012024-03-310000766704us-gaap:GeographicConcentrationRiskMemberus-gaap:AssetsTotalMember2023-01-012023-12-310000766704us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-03-310000766704us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310000766704us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-01-012024-03-310000766704us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-01-012023-03-31

(Mark One)

For the quarterly period ended March 31, 2024

For the transition period from                     to                      

 

(Exact name of registrant as specified in its charter) 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  þ  No  ¨

Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ  No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No  þ

As of April 26, 2024, Welltower Inc. had 597,916,197 shares of common stock outstanding.

 

Note: The consolidated balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements.

(In thousands, except per share data) 

(1) Includes amounts attributable to redeemable noncontrolling interests.

(2) Includes adjustment to the numerator for income (loss) attributable to OP Units and DownREIT Units.

Welltower Inc., an S&P 500 company headquartered in Toledo, Ohio, is driving the transformation of health care infrastructure. We invest with leading seniors housing operators, post-acute providers and health systems to fund the real estate and infrastructure needed to scale innovative care delivery models and improve people’s wellness and overall health care experience. Welltower Inc., a real estate investment trust (“REIT”), owns interests in properties concentrated in major, high-growth markets in the United States (“U.S.”), Canada and the United Kingdom (“U.K.”), consisting of seniors housing and post-acute communities and outpatient medical properties. 

We are structured as an umbrella partnership REIT under which substantially all of our business is conducted through Welltower OP LLC, the day-to-day management of which is exclusively controlled by Welltower Inc. Unless stated otherwise or the context otherwise requires, references to "Welltower" mean Welltower Inc. and references to "Welltower OP" mean Welltower OP LLC. References to "we," "us" and "our" mean collectively Welltower, Welltower OP and those entities/subsidiaries owned or controlled by Welltower and/or Welltower OP. Welltower's weighted average ownership in Welltower OP was 99.745% for the three months ended March 31, 2024. As of March 31, 2024, Welltower owned 99.726% of the issued and outstanding units of Welltower OP, with other investors owning the remaining 0.274% of outstanding units. We adjust the noncontrolling members' interest at the end of each period to reflect their interest in the net assets of Welltower OP.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (such as normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2024 are not necessarily an indication of the results that may be expected for the year ending December 31, 2024. For further information, refer to the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023.

In November 2023, the FASB issued Accounting Standards Update No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is to be applied retrospectively to all periods presented in the financial statements. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09")," which modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and disclosures.

The total purchase price for all properties acquired has been allocated to the tangible and identifiable intangible assets and liabilities at cost on a relative fair value basis. Liabilities assumed and any associated noncontrolling interests are reflected at fair value. The results of operations for these acquisitions have been included in our consolidated results of operations since the date of acquisition and are a component of the appropriate segments. Transaction costs primarily represent costs incurred with acquisitions, including due diligence costs, fees for legal and valuation services, termination of pre-existing relationships computed based on the fair value of the assets acquired, lease termination fees and other acquisition-related costs. Transaction costs directly related to asset acquisitions are capitalized as a component of purchase price and all other non-capitalizable costs are reflected in other expenses on our Consolidated Statements of Comprehensive Income. Our acquisition of properties are at times subject to earn out provisions based on the future operating performance of the acquired properties, which could result in incremental payments in the future. Our policy is to recognize such contingent consideration when the contingency is resolved and the consideration becomes payable.

The following is a summary of our real property investment activity by segment for the periods presented (in thousands):

(1) Primarily relates to the acquisition of assets previously financed as real estate loans receivable.

(2) Represents non-cash accruals for amounts to be paid in future periods for properties that converted, offset by amounts paid in the current period.

In February 2024, we entered into a definitive agreement to acquire 25 Seniors Housing Operating properties for a total purchase price of $969 million, which will be managed under the Affinity brand. The transaction is expected to close in the second quarter of 2024 and will be funded through a combination of cash and the assumption of $523 million of secured debt, subject to customary closing conditions and lender consents.

The following is a summary of the construction projects that were placed into service and began generating revenues during the periods presented (in thousands):

The following is a summary of our real estate intangibles, excluding those related to ground leases or classified as held for sale, as of the dates indicated (dollars in thousands):

The following is a summary of real estate intangible amortization income (expense) for the periods presented (in thousands):

We periodically sell properties for various reasons, including favorable market conditions, the exercise of tenant purchase options or reduction of concentrations (i.e., property type, relationship or geography). At March 31, 2024, 21 Seniors Housing Operating properties, one Triple-net property, and four Outpatient Medical properties with an aggregate real estate balance of $422,225,000 were classified as held for sale. In addition to the real property balances, secured debt balances of $171,292,000 and net other assets and (liabilities) of $21,925,000 are included in the Consolidated Balance Sheets related to the held for sale properties. Expected gross sales proceeds related to the held for sale properties are approximately $611,468,000, which includes non-cash consideration relating to 14 Canadian Revera properties discussed below.

During the three months ended March 31, 2024, we entered into a definitive agreement and subsequently closed on the sale of four Seniors Housing Operating properties. In conjunction with this transaction, an impairment charge of $23,795,000 was recognized related to two properties. Additionally, we recorded $15,584,000 of impairment charges related to six Seniors Housing Operating properties classified as held for sale and not yet sold as of March 31, 2024 for which the carrying value exceeded the estimated fair value less costs to sell. Impairment charges of $3,952,000 related to two Seniors Housing Operating properties classified as held for use for which the carrying value exceeded the estimated fair value were also recognized.

During the three months ended March 31, 2023, we recorded $12,629,000 of impairment charges related to three Seniors Housing Operating properties classified as held for sale for which the carrying value exceeded the estimated fair value less costs to sell, and one Seniors Housing Operating property classified as held for use for which the carrying value exceeded the estimated fair value.

Operating results attributable to properties sold or classified as held for sale which do not meet the definition of discontinued operations are not reclassified on our Consolidated Statements of Comprehensive Income. We recognized income (loss) from continuing operations before income taxes and other items from properties sold or classified as held for sale as of March 31, 2024 of $(37,190,000) and $(14,525,000) for the three months ended March 31, 2024 and 2023, respectively.

The following is a summary of our real property disposition activity for the periods presented (in thousands):

(1) Dispositions occurring in the three months ended March 31, 2024 include the disposition of an unconsolidated equity method investment that owned six properties.

During the quarter ended June 30, 2023, we entered into definitive agreements to dissolve our existing Revera joint venture relationships across the U.S., U.K. and Canada. The transactions include acquiring the remaining interests in 110 properties from Revera, while simultaneously selling interests in 31 properties to Revera.

In June 2023, we closed the U.K. portfolio portion of the transaction through the acquisition of the remaining ownership interest in 29 properties previously held in two separate consolidated joint venture structures in which we owned 75% and 90% of the interests in exchange for the disposition to Revera of our interests in four properties. In addition, we received cash from Revera of $107,341,000 relating to the net settlement of loans previously made to the joint ventures. Operations for the 29 retained properties were transitioned to Avery Healthcare.

Total proceeds related to the four properties disposed were $222,521,000, which included non-cash consideration from Revera of $241,728,000, comprised of the fair value of interests received by us of $198,837,000 and an allocation of Revera's noncontrolling interests of $42,891,000, partially offset by $9,049,000 of transaction-related expenses as well as the $10,158,000 of cash paid to equalize the value exchanged between the parties. We disposed of net real property owned of $224,208,000, resulting in a loss of $1,687,000 recognized within gain (loss) on real estate dispositions, net within our Consolidated Statements of Comprehensive Income. Consideration transferred to acquire the additional interests in the 29 properties was comprised of the fair value of interests transferred by us of $198,837,000 and $5,776,000 of cash paid for transaction-related expenses. We derecognized $180,497,000 of noncontrolling interests and $22,270,000 of liabilities previously due to Revera with an adjustment of $1,846,000 recognized in capital in excess of par value.

We closed the portion of the transactions predominantly related to the U.S. portfolio during the third quarter of 2023 through (i) the acquisition of the remaining interests in ten properties currently under development or recently developed by Sunrise Senior Living that were previously held within an equity method joint venture owned 34% by us and 66% by Revera, (ii) the disposition of our minority interests in 12 U.S. properties and one Canadian development project and (iii) the disposition of our 34% interest in the Sunrise Senior Living management company. We recorded net real estate investments of $479,525,000 related to the ten acquired and now consolidated properties, which was comprised of $31,456,000 of cash consideration and $448,069,000 of non-cash consideration. Non-cash consideration primarily includes $270,486,000 of assumed mortgage debt secured by the acquired properties, which was subsequently repaid in full by us immediately following the transaction, $47,734,000 of carryover investment from our prior 34% equity method ownership interest and $119,258,000 of fair value interests in the 13 properties transferred by us to Revera. We also derecognized $56,905,000 of equity method investments related to the 13 properties retained by Revera and recorded a gain on real estate dispositions of $62,075,000. In conjunction with this transaction, operations for two of the now wholly-owned properties, along with operations for 26 existing wholly-owned properties, transitioned to Oakmont Management Group.

The Canadian portfolio consists of 85 properties in a joint venture owned 75% by us and 25% by Revera. On April 1, 2024, we closed the Canadian portion of the transaction, which included acquiring Revera's interest in 71 properties and selling our interests in the remaining 14 properties. Operations for the 71 retained properties previously transitioned to new operators.

We lease land, buildings, office space and certain equipment. Many of our leases include a renewal option to extend the term from one to 25 years or more. Renewal options that we are reasonably certain to exercise are recognized in our right-of-use assets and lease liabilities.

The components of lease expense were as follows for the periods presented (in thousands):

(1) Includes short-term leases which are immaterial.

Supplemental balance sheet information related to leases in which we are the lessee is as follows (in thousands):

Substantially all of our operating leases in which we are the lessor contain escalating rent structures. Leases with fixed annual rental escalators are generally recognized on a straight-line basis over the initial lease period, subject to a collectability assessment. Rental income related to leases with contingent rental escalators is generally recorded based on the contractual cash rental payments due for the period. During the three months ended March 31, 2024, we wrote-off previously recognized straight-line rent receivable balances of $9,356,000 through a reduction of rental income, which relate to leases for which the collection of substantially all contractual lease payments was no longer probable.

Leases in our Triple-net and Outpatient Medical portfolios recognized under ASC 842, "Leases" (ASC 842), typically include some form of operating expense reimbursement by the tenant. For the three months ended March 31, 2024, we recognized $417,652,000 of rental income related to operating leases, of which $56,228,000 was for variable lease payments that primarily represents the reimbursement of operating costs such as common area maintenance expenses, utilities, insurance and real estate taxes. For the three months ended March 31, 2023, we recognized $384,059,000 of rental income related to operating leases, of which $53,794,000 was for variable lease payments.

For the majority of our Seniors Housing Operating segment, revenue from resident fees and services is predominantly service-based, and as such, resident agreements are accounted for under ASC 606, "Revenue from Contracts with Customers." Within that reportable segment, we also recognize revenue from residential seniors apartment leases in accordance with ASC 842. The amount of revenue related to these leases was $130,565,000 and $108,915,000 for the three months ended March 31, 2024 and 2023, respectively.

Loans receivable are recorded on our Consolidated Balance Sheets in real estate loans receivable, net of allowance for credit losses, or for non-real estate loans receivable, in receivables and other assets. Real estate loans receivable consists of mortgage loans and other real estate loans, which are primarily collateralized by a first, second or third mortgage lien, a leasehold mortgage on, or an assignment of the partnership interest in, the related properties, as well as corporate guarantees and/or personal guarantees. Non-real estate loans are generally corporate loans with no real estate backing. Interest income on loans is recognized as earned based upon the principal amount outstanding subject to an evaluation of the risk of credit loss. Accrued interest receivable was $32,027,000 and $31,798,000 as of March 31, 2024 and December 31, 2023, respectively, and is included in receivables and other assets on the Consolidated Balance Sheets. The following is a summary of our loans receivable (in thousands):

The following is a summary of our loan activity for the periods presented (in thousands):    

The allowance for credit losses on loans receivable is maintained at a level believed adequate to absorb potential losses in our loans receivable. The determination of the credit allowance is based on a quarterly evaluation of each of these loans, including general economic conditions and estimated collectability of loan payments. We evaluate the collectability of our loans receivable based on a combination of credit quality indicators, including, but not limited to, payment status, historical loan charge-offs, financial strength of the borrower and guarantors, and nature, extent, and value of the underlying collateral.

A loan is considered to have deteriorated credit quality when, based on current information and events, it is probable that we will be unable to collect all amounts due as scheduled according to the contractual terms of the loan agreement. For those loans we identified as having deteriorated credit quality, we determine the amount of credit loss on an individual basis. Placement on non-accrual status may be required. Consistent with this definition, all loans on non-accrual are deemed to have deteriorated credit quality. To the extent circumstances improve and the risk of collectability is diminished, we will return these loans to income accrual status. While a loan is on non-accrual status, any cash receipts are applied against the outstanding principal balance.

For the remaining loans we assess credit loss on a collective pool basis and use our historical loss experience for similar loans to determine the reserve for credit losses. The following is a summary of our loans by credit loss category (in thousands):